Year 2022 / Volume 29 / Supplement 1

Abstract PDF HTML

Cannabinoids Article

Some preclinical results of cannabinoids and pain

Rev. Soc. Esp. Dolor. 2022; 29(13): 3-9 / DOI: 10.20986/resed.2022.4033/2022

Carlos Goicoechea, Marina Sanz, Miguel Ángel Martínez, David Pascual, Eva María Sánchez


ABSTRACT

The role of the endocannabinoid system in the modulation of nociception and in the interpretation of those signals in known since the middle of the last century. The work carried out since then has made possible to better understand mechanisms of action involved and to synthesize different drugs able to modulate these signals. These drugs can be agonists, aimed at directly activating cannabinoid receptors, or substances that modulate the enzymes responsible for the synthesis and degradation of endocannabinoids. Pharmacologically, other substances present in the Cannabis sativa plant are also being studied, as well as synthetic derivatives obtained from these, which can bind, in addition to the aforementioned receptors, to other types of receptors involved in the physiology of the nociception. Results obtained to date demonstrate efficacy in multiple animal models of pain, both acute and chronic, both nociceptive and neuropathic, and offer new of research lines for the pharmacological treatment of chronic pain.



RESUMEN

El papel del sistema endocannabinoide en la modulación de la nocicepción y en la interpretación de estas señales se conoce desde mediados del siglo pasado. Los trabajos desarrollados desde entonces han permitido profundizar en los mecanismos de acción implicados y así poder sintetizar diversos fármacos capaces de modular estas señales. Estos fármacos pueden ser agonistas, dirigidos a activar directamente receptores cannabinoides, pero pueden igualmente ser sustancias que modulen las enzimas encargadas de las síntesis y degradación de los endocannabinoides. Farmacológicamente se están estudiando, además, otras sustancias presentes en la planta Cannabis sativa, así como derivados sintéticos obtenidos a partir de estas, que pueden unirse, además de a los receptores antes mencionados, a otros tipos de receptores implicados en la fisiología de la nocicepción. Los resultados obtenidos hasta el momento demuestran eficacia en múltiples modelos animales de dolor, tanto agudo como crónico, tanto nociceptivo como neuropático, y abren vías de investigación para el tratamiento farmacológico del dolor crónico.





Complete Article

Nuevo comentario

Security code:
CAPTCHA code image
Speak the codeChange the code
 

Comentarios

No comments in this article

Bibliografía

1. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34(5):605-13.
2. Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946-9.
DOI: 10.1126/science.1470919
3. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and a functional expression of the cloned cDNA. Nature. 1990;346(6284):561-4.
DOI: 10.1038/346561a0
4. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61-5.
DOI: 10.1038/365061a0
5. Salzet M, Breton C, Bisogno T, Di Marzo V. Comparative biology of the endocannabinoid system. Possible role in the immune response. Eur J Biochem. 2000;267(16):4917-27.
DOI: 10.1046/j.1432-1327.2000.01550.x
6. Elphick MR, Egertová M. The phylogenetic distribution and evolutionary origins of endocannabinoid signalling. Handb Exp Pharmacol. 2005;(168):283-97.
7. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol. 2005;(168):299-325.
8. Chiarlone A, Bellocchio L, Blázquez C, Resel E, Soria-Gómez E, Cannich A, et al. A restricted population of CB1 cannabinoid receptors with neuroprotective activity. Proc Natl Acad Sci U S A. 2014;111(22):8257-62.
DOI: 10.1073/pnas.1400988111
9. Downer EJ. Cannabinoids and innate immunity: taking a toll on neuroinflammation. ScientificWorldJournal 2011;11:855-65.
DOI: 10.1100/tsw.2011.84
10. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev. 2009;89:309-80.
DOI: 10.1152/physrev.00019.2008
11. Castillo PE, Younts TJ, Chávez AE, Hashimotodani Y. Endocannabinoid signaling and synaptic function. Neuron. 2012;76(1):70-81.
DOI: 10.1016/j.neuron.2012.09.020
12. Elphick MR, Egertová M. The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci. 2001;356(1407):381-408.
DOI: 10.1098/rstb.2000.0787
13. Walter L, Stella N. Cannabinoids and neuroinflammation. Br J Pharmacol. 2004;141(5):775-85.
DOI: 10.1038/sj.bjp.0705667
14. Mechoulam R, Gaoni Y. The absolute configuration of delta-1-tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett. 1967;12:1109-11..
DOI: 10.1016/S0040-4039(00)90646-4
15. Gregg LC, Jung KM, Spradley JM, Nyilas R, Suplita RL, Zimmer A, et al. Activation of type 5 metabotropic glutamate receptors and diacylglycerol lipase-α initiates 2-arachidonoylglycerol formation and endocannabinoid-mediated analgesia. J Neurosci. 2012;32(28):9457-68.
DOI: 10.1523/JNEUROSCI.0013-12.2012
16. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, Decosta BR, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA. 1990;87(5):1932-6.
DOI: 10.1073/pnas.87.5.1932
17. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, et al. An endocannabinoid mechanism for stress-induced analgesia. Nature. 2005;435(7045):1108-12.
DOI: 10.1038/nature03658
18. Martin WJ, Coffin PO, Attias E, Balinsky M, Tsou K, Walker JM. Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res. 1999;822(1-2):237-42.
DOI: 10.1016/S0006-8993(98)01368-7
19. Walker JM, Hohmann AG. Cannabinoid mechanisms of pain suppression. Handb Exp Pharmacol. 2005;168(168):509-54.
20. Walker JM, Huang SM. Cannabinoid Analgesia. Pharmacol Ther. 2002;95(2):127-35.
DOI: 10.1016/S0163-7258(02)00252-8
21. Guindon J, Beaulieu P. The role of the endogenous cannabinoid system in peripheral analgesia. Curr Mol Pharmacol. 2009;2(1):134-9.
DOI: 10.2174/1874467210902010134
22. Hohmann AG. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids. 2002;121(1-2):173-90.
DOI: 10.1016/S0009-3084(02)00154-8
23. Nyilas R, Gregg LC, Mackie K, Watanabe M, Zimmer A, Hohmann AG, et al. Molecular architecture of endocannabinoid signaling at nociceptive synapses mediating analgesia. Eur J Neurosci. 2009;29(10):1964-78.
DOI: 10.1111/j.1460-9568.2009.06751.x
24. Richardson JD, Aanonsen L, Hargreaves KM. Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol. 1998;345(2):145-53.
DOI: 10.1016/S0014-2999(97)01621-X
25. Sagar DR, Jhaveri M, Richardson D, Gray RA, De Lago E, Fernandez-Ruiz J, Barrett D, Kendall D, Chapman V. Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain. Eur J Neurosci. 2010;31(8):1414-22.
DOI: 10.1111/j.1460-9568.2010.07162.x
26. Woodhams SG, Wong A, Barrett DA, Bennett AJ, Chapman V, Alexander SPH. Spinal administration of the monoacylglycerol lipase inhibitor JZL184 produces robust inhibitory effects on nociceptive processing and the development of central sensitization in the rat. Br J Pharmacol. 2012;167:1609-19.
DOI: 10.1111/j.1476-5381.2012.02179.x
27. Sagar DR, Burston JJ, Woodhams SG, Chapman V. Dynamic changes to the endocannabinoid system in models of chronic pain. Philos Trans R Soc Lond B Biol Sci. 2012;367(1607):3300-11.
DOI: 10.1098/rstb.2011.0390
28. Woodhams SG, Chapman V, Finn DP, Hohmann AG, Neugebauer V. The cannabinoid system and pain. Neuropharmacology. 2017;124:105-20.
DOI: 10.1016/j.neuropharm.2017.06.015
29. Maione S, Morera E, Marabese I, Ligresti A, Luongo L, Ortar G, et al. Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms. Br J Pharmacol. 2008;155(5):775-82.
DOI: 10.1038/bjp.2008.308
30. Holt S, Comelli F, Costa B, Fowler CJ. Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Br J Pharmacol. 2005;146(3):467-76.
DOI: 10.1038/sj.bjp.0706348
31. Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, Vaughan CW. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol. 2006;147(3):281-8.
DOI: 10.1038/sj.bjp.0706510
32. Ahn K, Smith SE, Liimatta MB, Beidler D, Sadagopan N, Dudley DT, et al. Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. J Pharmacol Exp Ther. 2011;338(1):114-24.
DOI: 10.1124/jpet.111.180257
33. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA. 2002;99(16):10819-24.
DOI: 10.1073/pnas.152334899
34. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 1997;388(6644):773-8.
DOI: 10.1038/42015
35. Katona I, Freund T. Multiple functions of endocannabinoid signaling in the brain. Annu Rev Neurosci. 2012;35:529-58.
DOI: 10.1146/annurev-neuro-062111-150420
36. Ghosh S, Wise LE, Chen Y, Gujjar R, Mahadevan A, Cravatt BF, et al. The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model. Life Sci. 2013;92(8-9):498-505.
DOI: 10.1016/j.lfs.2012.06.020
37. Guindon J, Guijarro A, Piomelli D, Hohmann AG. Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain. Br J Pharmacol. 2011;163(7):1464-78.
DOI: 10.1111/j.1476-5381.2010.01192.x
38. Busquets-Garcia A, Puighermanal E, Pastor A, de la Torre R, Maldonado R, Ozaita A. Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry. 2011;70(5):479-86.
DOI: 10.1016/j.biopsych.2011.04.022
39. Kinsey SG, Nomura DK, O’Neal ST, Long JZ, Mahadevan A, Cravatt BF, et al. Inhibition of monoacylglycerol lipase attenuates Nonsteroidal anti-inflammatory drug-induced gastric hemorrhages in mice. J Pharmacol Exp Ther. 2011;338(3):795-802.
DOI: 10.1124/jpet.110.175778
40. Ignatowska-Jankowska BM, Ghosh S, Crowe MS, Kinsey SG, Niphakis MJ, Abdullah RA, et al. In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: Antinociceptive activity without cannabimimetic side effects. Br J Pharmacol. 2014;171(6):1392-407.
DOI: 10.1111/bph.12298
41. Ignatowska-Jankowska BM, Wilkerson JL, Mustafa M, Abdullah R, Niphakis M, Wiley JL, et al. Selective monoacylglycerol lipase inhibitors: antinociceptive versus cannabimimetic effects in mice. J Pharmacol Exp Ther. 2015;353(2):424-32.
DOI: 10.1124/jpet.114.222315
42. Flannery LE, Kerr DM, Finn DP, Roche M. FAAH inhibition attenuates TLR3-mediated hyperthermia, nociceptive- and anxiety-like behaviour in female rats. Behav Brain Res. 2018;353:11-20.
DOI: 10.1016/j.bbr.2018.06.030
43. Li M, Suchland KL, Ingram SL. Compensatory Activation of Cannabinoid CB2 receptor inhibition of GABA release in the rostral ventromedial medulla in inflammatory pain. J Neurosci. 2017;37(3):626-36.
DOI: 10.1523/JNEUROSCI.1310-16.2016
44. Deng L, Guindon J, Cornett BL, Makriyannis A, Mackie K, Hohmann AG. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal. Biol Psychiatry. 2015;77(5):475-87.
DOI: 10.1016/j.biopsych.2014.04.009
45. Parsons LH, Hurd YL. Endocannabinoid signalling in reward and addiction. Nat Rev Neurosci. 2015;16(10):579-94.
DOI: 10.1038/nrn4004
46. Sánchez EM, Bagües A, Martín Fontelles MI. Cannabinoids and muscular pain. Effectiveness of the local administration in rat. Eur J Pain. 2012;16(8):1116-27.
DOI: 10.1002/j.1532-2149.2012.00115.x
47. Wong H, Hossain S, Cairns BE. Delta-9-tetrahydrocannabinol decreases masticatory muscle sensitization in female rats through peripheral cannabinoid receptor activation. Eur J Pain. 2017;21(10):1732-42.
DOI: 10.1002/ejp.1085
48. Schuelert N, Zhang C, Mogg AJ, Broad LM, Hepburn DL, Nisenbaum ES, et al. Paradoxical effects of the cannabinoid CB2 receptor agonist GW405833 on rat osteoarthritic knee joint pain. Osteoarthritis Cartilage. 2010;18(11):1536-43.
DOI: 10.1016/j.joca.2010.09.005
49. Mechoulam R, Hanus L. Cannabidiol: An overview of some chemical and pharmacological aspects. Part I: Chemical aspects. Chem Phys Lipids. 2002;121(1-2):35-43.
DOI: 10.1016/S0009-3084(02)00144-5
50. Mechoulam R, Parker LA, Gallily R. Cannabidiol: An overview of some pharmacological aspects. J Clin Pharmacol. 2002;42(11 Suppl):11S-19S.
DOI: 10.1002/j.1552-4604.2002.tb05998.x
51. Burstein SH, Zurier RB. Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J. 2009;11(1):109-19.
DOI: 10.1208/s12248-009-9084-5
52. Whyte LS, Ryberg E, Sims NA, Ridge SA, Mackie K, Greasley PJ, et al. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A. 2009;106(38):16511-6.
DOI: 10.1073/pnas.0902743106
53. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 2000;97(17):9561-6.
DOI: 10.1073/pnas.160105897
54. Hammell DC, Zhang LP, Ma F, Abshire SM, McIlwrath SL, Stinchcomb AL, et al. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain. 2016;20(6):936-48.
DOI: 10.1002/ejp.818
55. Nachnani R, Raup-Konsavage WM, Vrana KE. The Pharmacological Case for Cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-12.
DOI: 10.1124/jpet.120.000340
56. Sepulveda DE, Morris DP, Raup-Konsavage WM, Sun D, Vrana KE, Graziane NM. Cannabigerol (CBG) attenuates mechanical hypersensitivity elicited by chemotherapy-induced peripheral neuropathy. Eur J Pain. 2022;26(9):1950-66.
DOI: 10.1002/ejp.2016
57. Kogan NM, Lavi Y, Topping LM, Williams RO, McCann FE, Yekhtin Z, et al. Novel CBG Derivatives Can Reduce Inflammation, Pain and Obesity. Molecules. 2021;26(18):5601.
DOI: 10.3390/molecules26185601
58. Bilbrey JA, Ortiz YT, Felix JS, McMahon LR, Wilkerson JL. Evaluation of the terpenes β-caryophyllene, α-terpineol, and γ-terpinene in the mouse chronic constriction injury model of neuropathic pain: possible cannabinoid receptor involvement. Psychopharmacology (Berl). 2022;239(5):1475-86.
DOI: 10.1007/s00213-021-06031-2
59. Pascual D, Goicoechea C, Suardíaz M, Martín MI. A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain 2005;118(1-2):23-34.
DOI: 10.1016/j.pain.2005.07.008
60. Rahn EJ, Zvonok AM, Thakur GA, Khanolkar AD, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther. 2008;327(2):584-91.
DOI: 10.1124/jpet.108.141994
61. Rahn EJ, Makriyannis A, Hohmann AG. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol. 2007;152(5):765-77.
DOI: 10.1038/sj.bjp.0707333
62. Desroches J, Charron S, Bouchard JF, Beaulieu P. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB1 and CB2 receptors. Neuropharmacology. 2014;77:441-52.
DOI: 10.1016/j.neuropharm.2013.10.006
63. Kehl LJ, Hamamoto DT, Wacnik PW, Croft DL, Norsted BD, Wilcox GL, et al. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain. 2003;103:175-86.
DOI: 10.1016/S0304-3959(02)00450-5
64. Khasabova IA, Gielissen J, Chandiramani A, Harding-Rose C, Odeh DA, Simone DA, et al. CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain. Behav Pharmacol. 2011;22:607-16.
DOI: 10.1097/FBP.0b013e3283474a6d
65. Curto-Reyes V, Llames S, Hidalgo A, Menéndez L, Baamonde A. Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain. Br J Phamacol. 2010;160:561-73.
DOI: 10.1111/j.1476-5381.2009.00629.x
66. Marino S, Idris AI. Emerging therapeutic targets in cancer induced bone disease: a focus on the peripheral type 2 cannabinoid receptor. Pharmacol Res. 2017;119:391-403.
DOI: 10.1016/j.phrs.2017.02.023
67. Guerrero AV, Quang P, Dekker N, Jordan RCK, Schmidt BL. Peripheral cannabinoids attenuate carcinoma-induced nociception in mice. Neurosci Lett. 2008;433:77-81.
DOI: 10.1016/j.neulet.2007.12.053
68. Uhelski MI, Cain DM, Harding-Rose C, Simone DA. The non-selective cannabinoid receptor agonist WIN55,212-2 attenuates responses of C-fiber nociceptors in a murine model of cancer pain. Neuroscience. 2013;247:84-94.
DOI: 10.1016/j.neuroscience.2013.05.003
69. Bushlin I, Rozenfeld R, Devi LA. Cannabinoid–opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol. 2010;10:80-6.
DOI: 10.1016/j.coph.2009.09.009
70. Finn DP, Haroutounian S, Hohmann AG, Krane E, Soliman N, Rice ASC. Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies. Pain. 2021;162(Suppl 1):S5-S25.
DOI: 10.1097/j.pain.0000000000002268
71. Bourke SL, Schlag AK, O'Sullivan SE, Nutt DJ, Finn DP. Cannabinoids and the endocannabinoid system in fibromyalgia: A review of preclinical and clinical research. Pharmacol Ther. 2022;240:108216.
DOI: 10.1016/j.pharmthera.2022.108216
72. Scuteri D, Rombolà L, Hamamura K, Sakurada T, Watanabe C, Sakurada S, et al. Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence. Biomed Pharmacother. 2022;146:112505.
DOI: 10.1016/j.biopha.2021.112505
73. Romero-Sandoval EA, Kolano AL, Alvarado-Vázquez PA. Cannabis and Cannabinoids for Chronic Pain. Curr Rheumatol Rep. 2017;19(11):67.
DOI: 10.1007/s11926-017-0693-1

Artículos relacionados

Pain trajectories and neuropathic pain symptoms following lung cancer surgery: a prospective cohort study

Rev. Soc. Esp. Dolor. 2023; 30(4): 270-283 / DOI: 10.1002/ejp.2265

Abdominopelvic neuropathic pain secondary to involvement of the anterior cutaneous, iliohypogastric, and ilioinguinal nerves: case report and review of the literature

Rev. Soc. Esp. Dolor. 2023; 30(4): 265-269 / DOI: 10.20986/resed.2024.4054/2023

Fibromyalgia, mitochondrial dysfunction, oxidative stress and inflammation: ozone as a multitarget treatment. Case report and review of literature

Rev. Soc. Esp. Dolor. 2023; 30(4): 258-264 / DOI: 10.20986/resed.2023.3987/2022

Characteristics and effectiveness of therapeutic exercise on cancer-related fatigue: a systematic review

Rev. Soc. Esp. Dolor. 2023; 30(4): 250-259 / DOI: 10.20986/resed.2023.4098/2023

Exosomes as a potential therapeutic strategy for low back pain: literature review

Rev. Soc. Esp. Dolor. 2023; 30(4): 243-249 / DOI: 10.20986/resed.2023.4075/2023

Care needs of intrathecal infusion therapy in patients with cancer pain

Rev. Soc. Esp. Dolor. 2023; 30(4): 227-242 / DOI: 10.20986/resed.2024.4099/2023

Continuous electrical stimulation for the treatment of trigeminal neuralgia. A systematic review

Rev. Soc. Esp. Dolor. 2023; 30(4): 217-226 / DOI: 10.20986/resed.2023.4043/2022

Problems and adverse reactions related to dipyrone in Colombia

Rev. Soc. Esp. Dolor. 2023; 30(4): 210-216 / DOI: 10.20986/resed.2023.4025/2022

Virtual reality increases pressure pain threshold and lowers anxiety in children compared with control and non-immersive control— randomized, crossover trial

Rev. Soc. Esp. Dolor. 2023; 30(3): 196-206

Persistent headache after craniotomy for meningioma: charting of the afferent pathways for nociception: a discussion

Rev. Soc. Esp. Dolor. 2023; 30(3): 191-195 / DOI: 10.20986/resed.2023.4069/2023

A case of neuralgic amyotrophy after vaccination against COVID-19

Rev. Soc. Esp. Dolor. 2023; 30(3): 187-190 / DOI: 10.20986/resed.2023.4021/2022

Ultrasound-guided ankle nerve block as adjuvant therapy in chronic pain after occupational injury.

Rev. Soc. Esp. Dolor. 2023; 30(3): 178-186 / DOI: 10.20986/resed.2023.4035/2022

Effectiveness of adding posterior capsule stretching after an exercise program in patients with subacromial impingement syndrome: a randomized clinical study

Rev. Soc. Esp. Dolor. 2023; 30(3): 168-177 / DOI: 10.20986/resed.2023.3927/2021

Pain paths among post-COVID-19 condition subjects: a prospective cross-sectional study with in-person evaluation

Rev. Soc. Esp. Dolor. 2023; 30(2): 131-145 / DOI: 10.1002/ejp.2094

Have the concepts of obstetric analgesia changed in the last 100 years?

Rev. Soc. Esp. Dolor. 2023; 30(2): 125-130 / DOI: 10.20986/resed.2023.4018/2022

Effect of therapeutic exercise in persons with sacroiliac joint dysfunction: a systematic review and meta-analysis

Rev. Soc. Esp. Dolor. 2023; 30(2): 95-108 / DOI: 10.20986/resed.2023.4034/2022

Knowledge, attitudes, and beliefs towards the disease in women with fibromyalgia. A qualitative study based on a focus group

Rev. Soc. Esp. Dolor. 2023; 30(2): 79-94 / DOI: 10.20986/resed.2023.4022/2022

Observational, prospective and multicenter study on the use of transmucosal fentanyl citrate in regular clinical practice for the control of breakthrough pain crises in cancer patients

Rev. Soc. Esp. Dolor. 2023; 30(2): 72-78 / DOI: 10.20986/resed.2023.4028/2022

Effects of transcranial direct current stimulation in pain and opioid consumption after spine surgery

Rev. Soc. Esp. Dolor. 2023; 30(1): 49-59 / DOI: 10.1002/ejp.1985

Pulsed radiofrequency of the supraescapular nerve in the treatment of painful shoulder

Rev. Soc. Esp. Dolor. 2023; 30(1): 36-48 / DOI: 10.20986/resed.2023.4046/2022

Effectiveness of cluneal nerve block for the treatment of chronic low back pain

Rev. Soc. Esp. Dolor. 2023; 30(1): 30-35 / DOI: 10.20986/resed.2023.4023/2022

Prevalence of glossodynia. Burning mouth syndrome and associated risk factors in the population of Ciudad Real

Rev. Soc. Esp. Dolor. 2023; 30(1): 15-29 / DOI: 10.20986/resed.2023.4045/2022

Review of the remission and management of a cancer related pain population to a pain unit. What can we improve?

Rev. Soc. Esp. Dolor. 2023; 30(1): 7-14 / DOI: 10.20986/resed.2023.4010/2022

Effectiveness of electroacupuncture and moxibustion in the treatment of postoperative anterior cruciate ligament graft pain with meniscal remodeling. Case study UNEVT 2022

Rev. Soc. Esp. Dolor. 2022; 29(3): 192-195 / DOI: 10.20986/resed.2022.4009/2022

Treatment of painful scars with 5 % lidocaine patch: clinical cases report

Rev. Soc. Esp. Dolor. 2022; 29(3): 187-191 / DOI: 10.20986/resed.2022.3997/2022

Long-term effectiveness of epidural steroid injections after new episodes of low back pain in older adults

Rev. Soc. Esp. Dolor. 2022; 29(3): 175-186 / DOI: 10.1002/ejp.1975

Usefulness of percutaneous basivertebral nerve thermorizotomy for the treatment of chronic low back pain. Literature review

Rev. Soc. Esp. Dolor. 2022; 29(3): 169-174 / DOI: 10.20986/resed.2022.4044/2022

Efficacy of physiotherapy on the anxiety and depression in patients with chronic pain: a systematic review

Rev. Soc. Esp. Dolor. 2022; 29(3): 157-168 / DOI: 10.20986/resed.2022.3994/2022

Psychological intervention program to promoted active coping in patients with chronic back pain

Rev. Soc. Esp. Dolor. 2022; 29(3): 149-156 / DOI: 10.20986/resed.2022.3993/2022

Single eco-guided intra-articular injection of hyaluronic acid in symptomatic coxarthrosis: retrospective study of the efficacy of two presentations

Rev. Soc. Esp. Dolor. 2022; 29(3): 140-148 / DOI: 10.20986/resed.2022.4014/2022

The impact of bupivacaine dose on post spinal shivering in cesarean section: a randomized trial

Rev. Soc. Esp. Dolor. 2022; 29(3): 132-139 / DOI: 10.20986/resed.2022.4039/2022

Pain and rehabilitation in Parsonage-Tuner syndrome due to SARS-CoV-2: a case report

Rev. Soc. Esp. Dolor. 2022; 29(2): 119-123 / DOI: 10.20986/resed.2022.3940/2021

Peripheral facial palsy following glossopharyngeal block: a case report

Rev. Soc. Esp. Dolor. 2022; 29(2): 114-118 / DOI: 10.20986/resed.2022.3963/2021

The biopsychosocial nature of chronic pelvic floor pain: a narrative review

Rev. Soc. Esp. Dolor. 2022; 29(2): 97-113 / DOI: 10.20986/resed.2022.3981/2022

Myofascial pain syndrome in the female pelvic floor musculature. Narrative review of the literature

Rev. Soc. Esp. Dolor. 2022; 29(2): 88-96 / DOI: 10.20986/resed.2022.3970/2022

Effects of hydrotherapy on pain in osteoarthritis and fibromyalgia: a narrative review

Rev. Soc. Esp. Dolor. 2022; 29(2): 78-87 / DOI: 10.20986/resed.2022.3955/2021

Impact of the use of patient-controlled epidural analgesia on pain reduction during labor in a hospital in southwestern colombia

Rev. Soc. Esp. Dolor. 2022; 29(2): 71-77 / DOI: 10.20986/resed.2022.3959/2021

Cross-sectional study on factors related to chronic pain and its care, according to sex

Rev. Soc. Esp. Dolor. 2022; 29(2): 61-70 / DOI: 10.20986/resed.2022.3968/2022

Attitudes and current knowledge of the spanish pain treatment specialist regarding medical cannabis

Rev. Soc. Esp. Dolor. 2022; 29(13): 52-57 / DOI: 10.20986/resed.2022.4032/2022

Practical aspects of product selection and titration with medical cannabis for chronic pain management

Rev. Soc. Esp. Dolor. 2022; 29(13): 43-51 / DOI: 10.20986/resed.2022.4031/2022

Medical cannabis treatment in patients with visceral chronic pain

Rev. Soc. Esp. Dolor. 2022; 29(13): 32-42 / DOI: 10.20986/resed.2022.4030/2022

Is medical cannabis useful for the treatment of fibromyalgia?

Rev. Soc. Esp. Dolor. 2022; 29(13): 27-31 / DOI: 10.20986/resed.2022.4029/2022

Cannabinoids in neuropathic pain: lights and shadows

Rev. Soc. Esp. Dolor. 2022; 29(13): 20-26 / DOI: 10.20986/resed.2022.4027/2022

Medical cannabis and cancer: benefits for cancer pain and other related symptoms

Rev. Soc. Esp. Dolor. 2022; 29(13): 14-19 / DOI: 10.20986/resed.2022.4026/2022

Current evidence of medical cannabis treatment in patients with chronic pain

Rev. Soc. Esp. Dolor. 2022; 29(13): 10-13 / DOI: 10.20986/resed.2022.4024/2022

The 4MAT model: an integrative strategy for teaching in health sciences

Rev. Soc. Esp. Dolor. 2022; 29(1): 57-58 / DOI: 10.20986/resed.2022.3989/2022

Bone pain management with opioid medication in a patient with Camurati-Engelmann disease: a case report

Rev. Soc. Esp. Dolor. 2022; 29(1): 51-55 / DOI: 10.20986/resed.2021.3930/2021

Complex regional pain syndrome, rehabilitation, pharmacotherapy, psychology.

Rev. Soc. Esp. Dolor. 2022; 29(1): 34-50 / DOI: 10.20986/resed.2022.3978/2022

Use of 8 % capsaicin patches for the treatment of lumbar neuropathic pain

Rev. Soc. Esp. Dolor. 2022; 29(1): 28-33 / DOI: 10.20986/resed.2022.3995/2022

Ultrasound guided interlaminar epidural steroid injection: the cumulative sum method (CUSUM) for performance evaluation

Rev. Soc. Esp. Dolor. 2022; 29(1): 21-27 / DOI: 10.20986/resed.2022.3988/2022

Evaluation of the analgesic efficacy of lumbar facet block as a function of the imaging technique used: ultrasound versus fluoroscopy

Rev. Soc. Esp. Dolor. 2022; 29(1): 15-20 / DOI: 10.20986/resed.2022.3969/2021

OFA in major surgery. Experience at a secondary level hospital

Rev. Soc. Esp. Dolor. 2022; 29(1): 8-14 / DOI: 10.20986/resed.2022.3991/2022

Pharmacological interventions in fibromyalgia; current considerations

Rev. Soc. Esp. Dolor. 2022; 29(1): 6-7 / DOI: 10.20986/resed.2022.4001/2022

Commentary to the article “Fibromyalgia: possible autoimmune disease. Consideration in the inflammatory and hormonal pattern”

Rev. Soc. Esp. Dolor. 2021; 28(6): 360-360 / DOI: 10.20986/resed.2022.3949/2021

Recommendations for the safe prescription of opioids in patients with a history or risk of abuse

Rev. Soc. Esp. Dolor. 2021; 28(6): 343-349 / DOI: 10.20986/resed.2022.3935/2021

Use of botulinum toxin for pain after amputation

Rev. Soc. Esp. Dolor. 2021; 28(6): 332-342 / DOI: 10.20986/resed.2022.3943/2021

Lumbar epidural steroids injections reduce catastrophism on the lumbosacral radicular syndrome

Rev. Soc. Esp. Dolor. 2021; 28(6): 325-331 / DOI: 10.20986/resed.2022.3947/2021

End-of-life transfusions in patients with an oncological diagnosis

Rev. Soc. Esp. Dolor. 2021; 28(6): 319-324 / DOI: 10.20986/resed.2022.3956/2021

Preliminary study on the evaluation of mechanical pressure pain and central pain modulation mechanisms by algometry in an anesthesia unit

Rev. Soc. Esp. Dolor. 2021; 28(6): 311-318 / DOI: 10.20986/resed.2022.3885/2021

Late onset of restless legs syndrome as a methadone withdrawal symptom in cancer patients: report of two cases

Rev. Soc. Esp. Dolor. 2021; 28(5): 298-300 / DOI: 10.20986/resed.2021.3889/2021

New opioids with different intracellular mechanism of action; is a new therapeutic window opening up?

Rev. Soc. Esp. Dolor. 2021; 28(5): 292-297 / DOI: 10.20986/resed.2021.3891/2021

A new paradigm for the treatment of knee osteoarthritis: the role of hyaluronic acid, platelet-rich plasma (PRP) and ozone in the modulation of inflammation: a review

Rev. Soc. Esp. Dolor. 2021; 28(5): 282-291 / DOI: 10.20986/resed.2021.3903/2021

Thalalgic triad. A new clinical entity from a case series

Rev. Soc. Esp. Dolor. 2021; 28(5): 276-281 / DOI: 10.20986/resed.2021.3941/2021

Efficacy and complications of analgesic techniques for the treatment of moderate to severe postoperative acute pain

Rev. Soc. Esp. Dolor. 2021; 28(5): 264-265 / DOI: 10.20986/resed.2021.3942/2021

Descriptive study on the profile of patients sent to the Chronic Pain Treatment Unit of the University Hospital of Gran Canaria Dr. Negrín (UTDC-HUGCDN) as a basis for the reorganization of this

Rev. Soc. Esp. Dolor. 2021; 28(5): 254-263 / DOI: 10.20986/resed.2021.3939/2021

Brachial plexus schwannoma and botulinum toxin: a case report

Rev. Soc. Esp. Dolor. 2021; 28(4): 242-245 / DOI: 10.20986/resed.2021.3924/2021

Treatment by ultrasound-guided neurolysis with 6 % aqueous phenol of the pain component for post-amputation neuromas: report of a clinical case

Rev. Soc. Esp. Dolor. 2021; 28(4): 239-241 / DOI: 10.20986/resed.2021.3928/2021

The unsolved problem of postoperative pain: critical analysis and prospects for improvement

Rev. Soc. Esp. Dolor. 2021; 28(4): 232-238 / DOI: 10.20986/resed.2021.3917/2021

Dorsal root ganlion pulsed radiofrequency for lumbosacral radicular pain: a narrative review

Rev. Soc. Esp. Dolor. 2021; 28(4): 219-231 / DOI: 10.20986/resed.2021.3882/2021

Pharmacological osteonecrosis in maxillofacial surgery, period 2013-2019

Rev. Soc. Esp. Dolor. 2021; 28(4): 211-218 / DOI: 10.20986/resed.2021.3837/2020

Clinical recommendations for rehabilitation of people with fibromyalgia. A narrative review

Rev. Soc. Esp. Dolor. 2021; 28(4): 194-210 / DOI: 10.20986/resed.2021.3932/2021

Psychological factors associated with the adherence to analgesic treatment in patients with chronic pain: systematic review of the literature

Rev. Soc. Esp. Dolor. 2021; 28(4): 181-193 / DOI: 10.20986/resed.2021.3922/2021

Persistent hiccups after epidural injection of betamethasone: a case report

Rev. Soc. Esp. Dolor. 2021; 28(2): 169-171 / DOI: 10.20986/resed.2021.3914/2021

Genicular nerve radiofrequency in osteoarthritis-related chronic knee pain

Rev. Soc. Esp. Dolor. 2021; 28(3): 154-168 / DOI: 10.20986/resed.2021.3900/2021

Observational and prospective study on the effectiveness and safety of the dorsal root ganglion stimulation in patients with refractory neuropathic pain

Rev. Soc. Esp. Dolor. 2021; 28(2): 148-156 / DOI: 10.20986/resed.2021.3879/2020

Prescribing habits for neuropathic pain management in Spain: results of the survey of the neuropathic pain working group of the Spanish Pain Society

Rev. Soc. Esp. Dolor. 2021; 28(3): 137-147 / DOI: 10.20986/resed.2021.3911/2021

Epidemiological profile of pain secondary to moderate diabetic peripheral neuropathy

Rev. Soc. Esp. Dolor. 2021; 28(2): 129-136 / DOI: 10.20986/resed.2021.3826/2020

Botulinum toxin for the treatment of myofascial pain syndrome

Rev. Soc. Esp. Dolor. 2021; 28(2): 100-110 / DOI: 10.20986/resed.2021.3902/2021

Postoperative ketamine efficacy in patients receiving chronic opioids undergoing spinal surgery

Rev. Soc. Esp. Dolor. 2021; 28(2): 92-99 / DOI: 10.20986/resed.2021.3825/2020

Risk of misuse of prescribed opioids in patients with chronic noncancer pain in a workers compensation system hospital in Chile

Rev. Soc. Esp. Dolor. 2021; 28(2): 82-91 / DOI: 10.20986/resed.2021.3845/2020

Evolution of low back pain in cancer patients treated with interventional pain management

Rev. Soc. Esp. Dolor. 2021; 28(2): 76-81 / DOI: 10.20986/resed.2021.3901/2021

Analgesic effectiveness of tapentadol in neuropathic pain secondary to post-laminectomy syndrome

Rev. Soc. Esp. Dolor. 2021; 28(2): 71-75 / DOI: 10.20986/resed.2021.3822/2020

Usefulness or necessity of ketamine in postoperative pain

Rev. Soc. Esp. Dolor. 2021; 28(2): 63-66 / DOI: 10.20986/resed.2021.3921/2021

Parsonage-turner after rabies vaccination due to bat bite: case report

Rev. Soc. Esp. Dolor. 2021; 28(1): 57-61 / DOI: 10.20986/resed.2021.3832/2020

Bilateral spinal erector plane block for pectus excavatum surgery in pediatric patient

Rev. Soc. Esp. Dolor. 2021; 28(1): 53-56 / DOI: 10.20986/resed.2021.3846/2020

Transfusions at the end of life. Review of some important considerations

Rev. Soc. Esp. Dolor. 2021; 28(1): 47-52 / DOI: 10.20986/resed.2021.3831/2020

Inflammatory mediators: its connection with chronic pain and associated problems. Review

Rev. Soc. Esp. Dolor. 2021; 28(1): 37-46 / DOI: 10.20986/resed.2021.3841/2020

Ozone and COVID-19: physiological bases and their therapeutic possibilities according to the evolutionary stage in SARS-CoV-2 infection

Rev. Soc. Esp. Dolor. 2021; 28(1): 27-36 / DOI: 10.20986/resed.2021.3810/2020

Management and perception of therapeutic adherence of breakthrough cancer pain by oncologists in Spain

Rev. Soc. Esp. Dolor. 2021; 28(1): 19-26 / DOI: 10.20986/resed.2021.3824/2020

Implementation and evaluation of a multimodal analgesia protocol for total knee arthroplasty including ultrasoundguided adductor canal block and periarticular local anesthetic infiltration

Rev. Soc. Esp. Dolor. 2021; 28(1): 9-18 / DOI: 10.20986/resed.2021.3847/2020

Interventional management of osteoarthritic pain

Rev. Soc. Esp. Dolor. 2021; 28(13): 85-90 / DOI: 10.20986/resed.2021.3853/2020

Platelet rich plasma and intra-articular mesenchymal stem cells in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 80-84 / DOI: 10.20986/resed.2021.3858/2020

Intra-articular botulinum toxin and ozone in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 73-79 / DOI: 10.20986/resed.2021.3857/2020

Infiltrations of steroids and hyaluronic acid in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 64-72 / DOI: 10.20986/resed.2021.3854/2020

New pharmacological targets for osteoarthritis induced pain

Rev. Soc. Esp. Dolor. 2021; 28(13): 57-63 / DOI: 10.20986/resed.2021.3863/2020

Opioids in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 49-56 / DOI: 10.20986/resed.2021.3855/2020

Review of the pharmacological treatment of osteoarthritis pain with paracetamol, non-steroid anti-inflammatory (NSAIDSS) and selective cyclooxygenase-2 inhibitors (COXIB)

Rev. Soc. Esp. Dolor. 2021; 28(13): 43-48 / DOI: 10.20986/resed.2021.3864/2020

News in the clinical practice guidelines regarding the treatment of the hip, knee and hands osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 38-42 / DOI: 10.20986/resed.2021.3870/2020

Experimental models for pain evaluation in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 18-30 / DOI: 10.20986/resed.2021.3872/2020

Ethiopathogenic mechanism of osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 11-17 / DOI: 10.20986/resed.2021.3851/2020

Epidemiology, clinical impact and therapeutic objectives in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 4-10 / DOI: 10.20986/resed.2021.3874/2020

Adaptation of the chronic pain unit of the Hospital Complex from Vigo to the state of alarm due to the SARS-CoV-2 pandemic

Rev. Soc. Esp. Dolor. 2020; 27(6): 392-393 / DOI: 10.20986/resed.2020.3827/2020

Effectiveness and current recommendation of manual therapy on hip osteoarthritis. An overview

Rev. Soc. Esp. Dolor. 2020; 27(6): 375-391 / DOI: 10.20986/resed.2021.3835/2020

Transitional pain clinic

Rev. Soc. Esp. Dolor. 2020; 27(6): 369-374 / DOI: 10.20986/resed.2020.3840/2020

Study of pain in rehabilitation treatments

Rev. Soc. Esp. Dolor. 2020; 27(6): 361-368 / DOI: 10.20986/resed.2020.3809/2020

Impact of group psychological intervention on conventional radiofrequency tributary patients

Rev. Soc. Esp. Dolor. 2020; 27(6): 349-360 / DOI: 10.20986/resed.2020.3830/2020

Calcific tendinitis of the shoulder: risk factors and effectiveness of iontophoresis with acetic acid 5 % plus ultrasound: prospective quasi-experimental study at 5 years with 138 cases

Rev. Soc. Esp. Dolor. 2020; 27(6): 340-348 / DOI: 10.20986/resed.2020.3842/2020

A 14-month physiotherapy follow up to a child with Sandifer syndrome

Rev. Soc. Esp. Dolor. 2020; 27(5): 329-331 / DOI: 10.20986/resed.2020.3816/2020

School of non-oncologic chronic pain patients and opioid treatment

Rev. Soc. Esp. Dolor. 2020; 27(5): 324-328 / DOI: 10.20986/resed.2020.3804/2020

Considerations for clinical examination of nonspecific neurogenic thoracic outlet syndrome

Rev. Soc. Esp. Dolor. 2020; 27(5): 316-323 / DOI: 10.20986/resed.2020.3834/2020

Opioid misuse in patients with cancer pain: an integrative systematic review of the literature

Rev. Soc. Esp. Dolor. 2020; 27(5): 306-315 / DOI: 10.20986/resed.2020.3801/2020

Therapeutic failure of the lumbar medial branch block and its relation to obesity. Retrospective cohort study

Rev. Soc. Esp. Dolor. 2020; 27(5): 298-305 / DOI: 10.20986/resed.2020.3829/2020

Identification of signs and symptoms for the diagnosis of discogenic low back pain: mapping review

Rev. Soc. Esp. Dolor. 2020; 27(5): 292-297 / DOI: 10.20986/resed.2020.3803/2020

Efficacy of lidocaine perfusions in fibromyalgia: a prospective cohort study

Rev. Soc. Esp. Dolor. 2020; 27(5): 287-291 / DOI: 10.20986/resed.2020.3796/2020

Back to the future in the treatment of postoperative acute pain

Rev. Soc. Esp. Dolor. 2020; 27(5): 285-286 / DOI: 10.20986/resed.2020.3850/2020

Splanchnic nerve block for the treatment of benign chronic abdominal pain. a case report and literature review

Rev. Soc. Esp. Dolor. 2020; 27(4): 273-277 / DOI: 10.20986/resed.2020.3818/2020

Continuous analgesic control in a patient with multiple rib fractures by placing a catheter in the deep plane of the erector muscle of the spine

Rev. Soc. Esp. Dolor. 2020; 27(4): 269-272 / DOI: 10.20986/resed.2020.3800/2020

Clinical pathophysiology in patients with sickle cell disease: the transition from acute to chronic pain

Rev. Soc. Esp. Dolor. 2020; 27(4): 257-268 / DOI: 10.20986/resed.2020.3814/2020

Gender determinants in the approach to chronic pain

Rev. Soc. Esp. Dolor. 2020; 27(4): 252-256 / DOI: 10.20986/resed.2020.3802/2020

Incidence of postmastectomy pain syndrome. Retrospective analysis

Rev. Soc. Esp. Dolor. 2020; 27(4): 246-251 / DOI: 10.20986/resed.2020.3797/2020

Sociodemographic and clinical characterization in patients with chronic back pain, Cienfuegos 2019

Rev. Soc. Esp. Dolor. 2020; 27(4): 239-245 / DOI: 10.20986/resed.2020.3798/2020

Spinal cord stimulation. Analysis of the diagnostic indications

Rev. Soc. Esp. Dolor. 2020; 27(4): 234-238 / DOI: 10.20986/resed.2020.3777/2019

Suboccipital decompression as an alternative in the treatment of pain secundary to occipital neuralgia: a case series

Rev. Soc. Esp. Dolor. 2020; 27(3): 221-226 / DOI: 10.20986/resed.2020.3791/2020

Analgesic effect of the capsaicin 8 % patch through the TRPV-1 receptor in a case of parkinson desease with located neuropathic pain

Rev. Soc. Esp. Dolor. 2020; 27(3): 216-22 / DOI: 10.20986/resed.2020.3786/2019

Spanish Pain Society (SPS). Healthcare recommendations for pain units in the face of progressive normalization of activity during the COVID-19 pandemic

Rev. Soc. Esp. Dolor. 2020; 27(3): 192-215 / DOI: 10.20986/resed.2020.3821/2020

Symptomatic treatment for migraña. Drugs used and related variables. Results of the european survey on work and migraine

Rev. Soc. Esp. Dolor. 2020; 27(3): 178-191 / DOI: 10.20986/resed.2020.3744/2019

Characteristics of patients suffering mild to severe pain treated with orodispersible tablets of paracetamol 325 mg/tramadol HCL 37,5mg (Paxiflas®) in comparison with other oral formulations containing the same combination. PROPAX study

Rev. Soc. Esp. Dolor. 2020; 27(3): 168-177 / DOI: 10.20986/resed.2020.3771/2019

Biomechanical factors related to surgical outcomes on patients treated with lumbar arthrodesis in a high complexity center in Colombia

Rev. Soc. Esp. Dolor. 2020; 27(3): 160-167 / DOI: 10.20986/resed.2020.3759/2019

Drug consumption used for musculoskeletal pain treatment in a cohort of blue-collar workers in Zaragoza (Spain)

Rev. Soc. Esp. Dolor. 2020; 27(3): 150-159 / DOI: 10.20986/resed.2020.3749/2019

Intraoperative methadone; an island among opioid free anesthesia drugs?

Rev. Soc. Esp. Dolor. 2020; 27(2): 140-142 / DOI: 10.20986/resed.2020.3789/2019

Clinical experience with the implementation of a postdural puncture headache multidisciplinary protocol

Rev. Soc. Esp. Dolor. 2020; 27(2): 133-137 / DOI: 10.20986/resed.2020.3782/2019

Management of breakthrough pain associated with the cure of skin ulcers

Rev. Soc. Esp. Dolor. 2020; 27(2): 113-126 / DOI: 10.20986/resed.2020.3755/2019

Efficacy of a preincisional analgesic strategy with ibuprofen, paracetamol and dexamethasone in laparoscopic cholecystectomy. Prospective observational study

Rev. Soc. Esp. Dolor. 2020; 27(2): 104-112 / DOI: 10.20986/resed.2020.3778/2019

E-consults, a new tool for pain management. Results of its implementation in an organizational structure of integrated management (EOXI)

Rev. Soc. Esp. Dolor. 2020; 27(2): 97-103 / DOI: 10.20986/resed.2020.3756/2019

Ethical problems in the management of pain. Qualitative study through open reflection interview

Rev. Soc. Esp. Dolor. 2020; 27(2): 89-96 / DOI: 10.20986/resed.2020.3729/2019

Intra-articular ozone modulates inflammation, ameliorates pain and stiffness, improves function and has anabolic effect on knee osteoarthritis: a prospective quasiexperimental before-and-after study, 115 patients

Rev. Soc. Esp. Dolor. 2020; 27(2): 78-88 / DOI: 10.20986/resed.2020.3775/2019

Altruistic conduct: a behavioral strategy to decrease the perception of pain?

Rev. Soc. Esp. Dolor. 2020; 27(2): 76-77 / DOI: 10.20986/resed.2020.3806/2020

Dimethyl fumarate: from an antipsoriatic drug to a promising antineuropathic drug

Rev. Soc. Esp. Dolor. 2020; 27(2): 74-75 / DOI: 10.20986/resed.2020.3805/2020

Review of the impact of acupuncture treatment on the management of nonspecific low back pain

Rev. Soc. Esp. Dolor. 2020; 27(1): 53-58 / DOI: 10.20986/resed.2020.3762/2019

Effectiveness of the association of lacosamide in trigeminal neuralgia

Rev. Soc. Esp. Dolor. 2020; 27(1): 50-52 / DOI: 10.20986/resed.2019.3738/2019

Peripheral acting Mu opioid receptor antagonists in the treatment of the opioid-induced constipation: review

Rev. Soc. Esp. Dolor. 2020; 27(1): 37-49 / DOI: 10.20986/resed.2020.3717/2018

Effectiveness of patient-controlled analgesia in acute and chronic pain after cardiac surgery: a prospective study

Rev. Soc. Esp. Dolor. 2020; 27(1): 24-36 / DOI: 10.20986/resed.2020.3747/2019

Efficacy of pregabalin, gabapentin and duloxetine in neuropathic pain verified by the p-curve analysis

Rev. Soc. Esp. Dolor. 2020; 27(1): 16-23 / DOI: 10.20986/resed.2020.3727/2019

Quasi-experimental study on effectiveness of music therapy to reduce anxiety before an interventional technique in the pain unit

Rev. Soc. Esp. Dolor. 2020; 27(1): 7-15 / DOI: 10.20986/resed.2020.3767/2019

Abducens nerve palsy associated with dural puncture and neurovascular compression

Rev. Soc. Esp. Dolor. 2019; 26(6): 376-378 / DOI: 10.20986/resed.2019.3722/2018

Considerations for the use of evidence-based practice in the management of people with pain

Rev. Soc. Esp. Dolor. 2019; 26(6): 374-375 / DOI: 10.20986/resed.2019.3712/2018

Intravenous perioperative ketamine, an old known who returns to stay?

Rev. Soc. Esp. Dolor. 2019; 26(6): 372-374 / DOI: 10.20986/resed.2019.3703/2018

Intratecal baclophene for the treatment of pain and spasticity in stiff man syndrome: a case report

Rev. Soc. Esp. Dolor. 2019; 26(6): 368-371 / DOI: 10.20986/resed.2019.3745/2019

Key factors governing spinal cord opioid bioavailability in the management of acute pain

Rev. Soc. Esp. Dolor. 2019; 26(6): 359-367 / DOI: 10.20986/resed.2019.3737/2019

Neurolytic procedures for pancreatic cáncer pain: a systematic review and a proposal for an algorithm treatment

Rev. Soc. Esp. Dolor. 2019; 26(6): 342-358 / DOI: 10.20986/resed.2019.3715/2018

Correlation study between diagnostic opportunity and pain severity in patients with fibromyalgia who enter the Nononcological Chronic Pain Unit at the San Borja Arriarán Clinical Hospital

Rev. Soc. Esp. Dolor. 2019; 26(6): 331-336 / DOI: 10.20986/resed.2019.3690/2018

Correlation between pain and radiological parameters in patients older than 60 years of age with distal radius fracture

Rev. Soc. Esp. Dolor. 2019; 26(6): 324-330 / DOI: 10.20986/resed.2019.3720/2018

Pyoderma gangrenosum, undocumented complication of a spinal cord stimulation

Rev. Soc. Esp. Dolor. 2019; 26(5): 309-312 / DOI: 10.20986/resed.2019.3725/2019

Cervical epidural anesthesia and analgesia for upper limb surgery

Rev. Soc. Esp. Dolor. 2019; 26(5): 304-308 / DOI: 10.20986/resed.2019.3686/2018

Applicability of scales/indicators for pain monitoring in critically ill patients incapable of verbalizing: a systematic review of the literature

Rev. Soc. Esp. Dolor. 2019; 26(5): 293-303 / DOI: 10.20986/resed.2019.3726/2019

The medical doctors who perform their care and research work in pain units in the use of the internet: identification, characterization and determinants

Rev. Soc. Esp. Dolor. 2019; 26(5): 284-292 / DOI: 10.20986/resed.2019.3713/2018

Validation of the coping strategies to chronic pain reduced questionnaire in the cienfuegan population with chronic back pain (2017-2018)

Rev. Soc. Esp. Dolor. 2019; 26(5): 276-283 / DOI: 10.20986/resed.2019.3732/2019

New strategies for postoperative pain control in tonsillectomy surgery. Is all that glitters gold?

Rev. Soc. Esp. Dolor. 2019; 26(5): 270-275 / DOI: 10.20986/resed.2019.3742/2019

Epidural betamethasone injection in lumbosacral radicular syndrome: effi cacy evaluation for interlaminar and transforaminal approaches

Rev. Soc. Esp. Dolor. 2019; 26(5): 263-269 / DOI: 10.20986/resed.2019.3700/2018

NMDA antagonism in the treatment of cluster headache

Rev. Soc. Esp. Dolor. 2019; 26(4): 247-250 / DOI: 10.20986/resed.2019.3710/2018

Orofacial pain in the dental clinic

Rev. Soc. Esp. Dolor. 2019; 26(4): 233-242 / DOI: 10.20986/resed.2019.3724/2019

Role of depressive symptomatology, catastrophism and expectation in the efficacy of interventional treatment in chronic low back pain

Rev. Soc. Esp. Dolor. 2019; 26(4): 227-232 / DOI: 10.20986/resed.2019.3704/2018

Characterization of pain in patients with breast cancer attending the Oncology Unit of the San José Hospital

Rev. Soc. Esp. Dolor. 2019; 26(4): 221-226 / DOI: 10.20986/resed.2019.3692/2018

Comparative analysis of vital signs in acutely hospitalized patients according to the pain intensity

Rev. Soc. Esp. Dolor. 2019; 26(4): 215-220 / DOI: 10.20986/resed.2019.3707/2018

Combination of pulsed and conventional radiofrecuency at low temperature in infraorbital nerve neuralgia. It is a role model?

Rev. Soc. Esp. Dolor. 2019; 26(4): 211-212 / DOI: 10.20986/resed.2019.3753/2019

Erector spinae plane block for multiple unilateral ribs fractures.

Rev. Soc. Esp. Dolor. 2019; 26(3): 199-202 / DOI: 10.20986/resed.2019.3687/2018

Pain in Parkinson's disease. A look at a little known aspect of this pathology

Rev. Soc. Esp. Dolor. 2019; 26(3): 184-198 / DOI: 10.20986/resed.2019.3733/2019

Information and communication technologies applied among medical professionals who perform pain treatment

Rev. Soc. Esp. Dolor. 2019; 26(3): 175-183 / DOI: 10.20986/resed.2019.3709/2018

Pulsed radiofrequency of the dorsal root ganglion for chronic lumbosacral radicular syndrome refractory to epidural steroid injections

Rev. Soc. Esp. Dolor. 2019; 26(3): 166-174 / DOI: 10.20986/resed.2019.3702/2018

Optimization of postoperative pain management based on a new technological tool. Pain map

Rev. Soc. Esp. Dolor. 2019; 26(3): 154-165 / DOI: 10.20986/resed.2019.3696/2018

Sublingual fentanyl for the treatment of breakthrough cancer pain during allergic reactions to chemotherapy infusion

Rev. Soc. Esp. Dolor. 2019; 26(3): 148-153 / DOI: 10.20986/resed.2018.3689/2018

Recent advances in the use of light in pain research. Implications in physiology and pharmacology

Rev. Soc. Esp. Dolor. 2019; 26(3): 146-147 / DOI: 10.20986/resed.2019.3743/2019

Situation of acute postoperative pain in the Spanish National Health System. Icts help to reach a “pain-free” hospital an primary care

Rev. Soc. Esp. Dolor. 2019; 26(3): 139-143 / DOI: 10.20986/resed.2019.3739/2019

Explanations on the article “Recommendations based on evidence for the management of neuropathic pain (review of the literature)”

Rev. Soc. Esp. Dolor. 2019; 26(2): 134-137 / DOI: 10.20986/resed.2019.3723/2019

Occipital neuralgia during stimulation trial period of SCS in failed back surgery sindrome

Rev. Soc. Esp. Dolor. 2019; 26(2): 126-127 / DOI: 10.20986/resed.2016.3514/2016

Motor block after caudal epidural infiltration: a case report

Rev. Soc. Esp. Dolor. 2019; 26(2): 120-123 / DOI: 10.20986/resed.2018.3669/2018

Myofascial pain syndrome as a cause of postoperative acute pain in hip surgery

Rev. Soc. Esp. Dolor. 2019; 26(2): 117-119 / DOI: 10.20986/resed.2019.3655/2018

Dexmedetomidine as peripheral nerve block adjuvant

Rev. Soc. Esp. Dolor. 2019; 26(2): 103-115 / DOI: 10.20986/resed.2018.3695/2018

Fast opioid detoxification

Rev. Soc. Esp. Dolor. 2019; 26(2): 95-102 / DOI: 10.20986/resed.2019.3681/2018

Effectiveness of hand crossing to produce analgesia in patients with chronic pain of the upper limb

Rev. Soc. Esp. Dolor. 2019; 26(2): 81-88 / DOI: 10.20986/resed.2019.3674/2018

Profiles of personality and resilience in chronic pain: utility of the CDRISC-10 to discriminate between resilient and vulnerable types

Rev. Soc. Esp. Dolor. 2019; 26(2): 72-80 / DOI: 10.20986/resed.2018.3670/2018

Oxytocin and chronic pain in humans

Rev. Soc. Esp. Dolor. 2019; 26(1): 52-58 / DOI: 10.20986/resed.2018.3664/2018

Influence of psychosocial factors in the experience of musculoskeletal pain: a literatura review

Rev. Soc. Esp. Dolor. 2019; 26(1): 44-51 / DOI: 10.20986/resed.2018.3679/2018

Project adapta: adequacy of treatment in breakthrough cancer pain

Rev. Soc. Esp. Dolor. 2019; 26(1): 31-43 / DOI: 10.20986/resed.2018.3661/2018

Psychosocial factors in chronic cancer pain: a Delphi study

Rev. Soc. Esp. Dolor. 2019; 26(1): 21-30 / DOI: 10.20986/resed.2018.3658/2018

Dexmedetomidine versus endovenous lidocaine in breakthrough pain control and functionality in patients with lumbar stenosis

Rev. Soc. Esp. Dolor. 2019; 26(1): 14-20 / DOI: 10.20986/resed.2018.3656/2018

Effects of multimodal treatment in patients with complex regional pain syndrome type 1 with, at least, 6 months of evolution: a descriptive study

Rev. Soc. Esp. Dolor. 2019; 26(1): 6-13 / DOI: 10.20986/resed.2018.3651/2018

Dysphonia as side-effect dose-dependent during treatment with duloxetine

Rev. Soc. Esp. Dolor. 2018; 25(6): 359-359 / DOI: 10.20986/resed.2017.3528/2016

Evidence-based recommendations for the management of neuropathic pain (review of the literature)

Rev. Soc. Esp. Dolor. 2018; 25(6): 349-358 / DOI: 10.20986/resed.2018.3673/2018

Changes in intraocular pressure in patients with trigeminal neuralgia subject to radio frequency of the Gasserian ganglion

Rev. Soc. Esp. Dolor. 2018; 25(6): 342-348 / DOI: 10.20986/resed.2018.3657/2018

Opinaudit study: clinical uses in breakthrough pain, is scientific evidence being followed up?

Rev. Soc. Esp. Dolor. 2018; 25(6): 325-334 / DOI: 10.20986/resed.2018.3634/2017

Use of major opioids for control of pain in hospitalized patients

Rev. Soc. Esp. Dolor. 2018; 25(6): 318-324 / DOI: 10.20986/resed.2018.3629/2017

Proctalgia and pudendal nerve entrapment: an association to know

Rev. Soc. Esp. Dolor. 2018; 25(6): 311-317 / DOI: 10.20986/resed.2018.3623/2017

¿Tratamos bien el dolor irruptivo?

Rev. Soc. Esp. Dolor. 2018; 25(6): 309-310 / DOI: 10.20986/resed.2018.3716/2018

Radiofrequency thermal and splanchnics nerves block

Rev. Soc. Esp. Dolor. 2018; 25(5): 303-304 / DOI: 10.20986/resed.2016.3509/2016

Implications of bioethics in the treatment of chronic pain: the change of paradigms

Rev. Soc. Esp. Dolor. 2018; 25(5): 291-300 / DOI: 10.20986/resed.2018.3666/2018

Farmacologic adyuvants with saving effect of opioids in the perioperative period

Rev. Soc. Esp. Dolor. 2018; 25(5): 278-290 / DOI: 10.20986/resed.2018.3663/2018

Experience in two hospitals about the observation of pain responses in hospitalized preterm infants

Rev. Soc. Esp. Dolor. 2018; 25(5): 271-277 / DOI: 10.20986/resed.2018.3633/2017

Platelet-rich plasma in treating peripheral neuropathic pain. Preliminary report

Rev. Soc. Esp. Dolor. 2018; 25(5): 263-270 / DOI: 10.20986/resed.2017.3625/2017

Pain in the elderly and in patients with cognitive deficit. A DELPHI study

Rev. Soc. Esp. Dolor. 2018; 25(5): 251-262 / DOI: 10.20986/resed.2017.3621/2017

Chrono study: prevalence of breakthrough pain among patients with non-cancer chronic pain in Andalusia, Spain

Rev Soc Esp Dolor 2018; 25(4): 214-221 / DOI: 10.20986/resed.2017.3626/2017

Trial therapy on laterality and motor imagery and selective glenohumeral muscle activation in patients with massive rotator cuff tear: case series

Rev Soc Esp Dolor 2018; 25(4): 197-206 / DOI: 10.20986/resed.2017.3610/2017

Expenditure, prescription and consumption of analgesic drugs before and during the economic crisis

Rev Soc Esp Dolor 2018; 25(3): 155-162 / DOI: 10.20986/resed.2017.3609/2017

Sex and pain: sexual satisfaction and sexual function in a sample of patients with chronic, non-pelvic pain

Rev Soc Esp Dolor 2018; 25(3): 145-154 / DOI: 10.20986/resed.2018.3600/2017

Bibliometric analysis of the Journal of the Spanish Pain Society: 2007-2016

Rev Soc Esp Dolor 2018; 25(3):170-177 / DOI: 10.20986/resed.2018.3627/2017

Painometer v2®: a mobile application certified for monitoring patients with pain

Rev Soc Esp Dolor 2018; 25(2):112-120 / DOI: 10.20986/resed.2017.3555/2016

Analgesic efficacy of topical sevoflurane on wounds

Rev Soc Esp Dolor 2018; 25(2): 106-111 / DOI: 10.20986/resed.2017.3617/2017

Pharmacological management of acute postoperative pain in Spain. Data from the national survey by the Spanish Pain Society (SED)

Rev Soc Esp Dolor 2018; 25(2): 70-85 / DOI: 10.20986/resed.2017.3593/2017

Potential uses of Mirtazapine in palliative care beyond its antidepressant effect

Rev Soc Esp Dolor 2018; 25(1): 37-44 / DOI: 10.20986/resed.2017.3575/2017

Prevalence of pain in patients hospitalized in Metabolic Intensive Care Units with orotracheal intubation and under sedation, measured with the COMFORT scale

Rev Soc Esp Dolor 2018; 25(1): 7-12 / DOI: 10.20986/resed.2017.3581/2017

Pain management in cancer patients receiving radiotherapy: GORVAMUR study, a prospective, observational, epidemiological study

Rev Soc Esp Dolor 2017; 24(5): 241-255 / DOI: 10.20986/resed.2017.3570/2017

Epidural analgesia vs. surgical wound analgesia to control acute post-operative pain in open colon surgery

Rev Soc Esp Dolor 2017; 24(5): 234-240 / DOI: 10.20986/resed.2017.3559/2016

CAD-R. Chronic pain coping questionnaire: confirmatory factor analysis. Are there individual differences in gender, age and type of pain?

Rev Soc Esp Dolor 2017; 24(5): 224-233 / DOI: 10.20986/resed.2017.3558/2016

Intervention of manual motor skill exercises on pain and functionality in adults subjects with rheumatoid arthritis: case series

Rev Soc Esp Dolor 2017; 24(6): 294-303 / DOI: 10.20986/resed.2017.3576/2017

The effectiveness of electrical spinal-cord stimulation in type i complex regional pain syndrome. A literature review

Rev Soc Esp Dolor 2017; 24(4): 169-178 / DOI: 10.20986/resed.2016.3501/2016

Paxiflas®: new FDT combination of tramadol/paracetamol for treating moderate to severe pain

Rev Soc Esp Dolor 2017; 24(2):59-67 / DOI: 10.20986/resed.2017.3565/2017

The predictive role of rumination and trait mindfulness in pain and negative mood after a sport injury: a longitudinal study

Rev Soc Esp Dolor 2017; 24(3):125-131 / DOI: 10.20986/resed.2017.3495/2016

Prevalence of breakthrough pain associated with chronic low back pain in Andalusia (COLUMBUS study)

Rev Soc Esp Dolor 2017; 24(3):116-124 / DOI: 10.20986/resed.2017.3548/2016

Effectiveness of hyaluronic acid intra-articular injections in treating knee osteoarthritis: results of a series of cases treated in a Pain Unit

Rev Soc Esp Dolor 2017; 24(2): 74-84 / DOI: 10.20986/resed.2016.3485/2016

Prescribing strong opioids in patients with non-cancer pain: a description of their characteristics in an area of primary healthcare assistance

Rev Soc Esp Dolor 2017; 24(1): 19-26 / DOI: 10.20986/resed.2016.3471/2016

Factors associated with pain intensity in Mexican patients hospitalized in postoperative period

Rev Soc Esp Dolor 2017; 24(1): 4-10 / DOI: 10.20986/resed.2016.3442/2016

Instrucciones para citar

Goicoechea C, Sanz M, Martínez M, Pascual D, Sánchez E. Some preclinical results of cannabinoids and pain. Rev Soc Esp Dolor 2022; 29(13): 3-9 / DOI: 1020986/resed20224033/2022


Descargar a un gestores de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica

Este artículo ha sido visitado 10192 veces.
Este artículo ha sido descargado 2 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Aceptado: 27/09/2022

Publicado: 28/10/2022


Compartir

Este artículo aun no tiene valoraciones.
Reader rating:
Rate this article:
Send by e-mail
© 2024 Revista de la Sociedad Española del Dolor
ISSN: 1134-8046   e-ISSN: 2254-6189

       Indexada en:
Política de Privacidad